CoChat

Targeting cancer cell metabolism in pancreatic adenocarcinoma

Open access
Cohen, Romain, Neuzillet, Cindy, Tijeras-Raballand, Annemilaï, Faivre, Sandrine, de Gramont, Armand, Raymond, Eric · 2015 · Oncotarget
Cited by 120

The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.

Abstract

// Romain Cohen 1 , Cindy Neuzillet 1, 2 , Annemilaï Tijeras-Raballand 3 , Sandrine Faivre 4 , Armand de Gramont 5 , Eric Raymond 4 1 INSERM U728, Beaujon University Hospital (AP-HP – PRES Paris 7 Diderot), Clichy La Garenne, France 2 Department of Medical Oncology, Henri Mondor University Hospital, Créteil, France 3 AAREC Filia Research, Translational Department, Boulogne-Billancourt, France 4 Medical Oncology, Department of Oncology, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland 5 New Drug Evaluation Laboratory, Centre of Experimental Therapeutics and Medical Oncology, Department of Oncology, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland Correspondence to: Eric Raymond, e-mail: eric.raymond@chuv.ch Keywords: glycolysis, warburg effect, metformin, glutamine, hypoxia Received: March 08, 2015 Accepted: May 29, 2015 Published: June 10, 2015 ABSTRACT Pancreatic ductal adenocarcinoma (PDAC) is expected to become the second leading cause of cancer death by 2030. Current therapeutic options are limited, warranting an urgent need to explore innovative treatment strategies. Due to specific microenvironment constraints including an extensive desmoplastic stroma reaction, PDAC faces major metabolic challenges, principally hypoxia and nutrient deprivation. Their connection with oncogenic alterations such as KRAS mutations has brought metabolic reprogramming to the forefront of PDAC therapeutic research. The Warburg effect, glutamine addiction, and autophagy stand as the most important adaptive metabolic mechanisms of cancer cells themselves, however metabolic reprogramming is also an important feature of the tumor microenvironment, having a major impact on epigenetic reprogramming and tumor cell interactions with its complex stroma. We present a comprehensive overview of the main metabolic adaptations contributing to PDAC development and progression. A review of current and future therapies targeting this range of metabolic pathways is provided.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.18632/oncotarget.4160

Cites

49 of 49 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 49 references

Cited by

Metadata

Authors
Cohen, R., Neuzillet, C., Tijeras-Raballand, A., Faivre, S., de Gramont, A., & Raymond, E.
Venue
Oncotarget
Published
2015-06-10
Volume
6
Issue
19
Pages
16832-16847
ISSN
1949-2553 (ISSN-L)
OpenAlex
W1775874433
Cited by
120
References
49
FWCI
6.58
Type
journal article
Language
en
Open access
diamond

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.